IN2014DN10798A - - Google Patents

Info

Publication number
IN2014DN10798A
IN2014DN10798A IN10798DEN2014A IN2014DN10798A IN 2014DN10798 A IN2014DN10798 A IN 2014DN10798A IN 10798DEN2014 A IN10798DEN2014 A IN 10798DEN2014A IN 2014DN10798 A IN2014DN10798 A IN 2014DN10798A
Authority
IN
India
Prior art keywords
compositions
gluten
cba
administered
subject
Prior art date
Application number
Inventor
Francesca Romana Fasano
Andrea Luigi Budelli
Original Assignee
Heinz Co H J
Francesca Romana Fasano
Andrea Luigi Budelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heinz Co H J, Francesca Romana Fasano, Andrea Luigi Budelli filed Critical Heinz Co H J
Publication of IN2014DN10798A publication Critical patent/IN2014DN10798A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention features compositions and methods for treating gluten related disorders. We describe compositions comprising one or more metabolites produced by CBA L74 International Depository Accession Number LMG P 24778 that reduce cellular entry of gliadin peptides. The compositions may include a physiologically acceptable carrier for example a food product or a pharmaceutical carrier. The compositions can be administered to a subject having a gluten related disorder for example celiac disease or gluten sensitivity.
IN10798DEN2014 2012-06-18 2013-06-18 IN2014DN10798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661105P 2012-06-18 2012-06-18
US201261725693P 2012-11-13 2012-11-13
PCT/US2013/046286 WO2013192163A1 (en) 2012-06-18 2013-06-18 Gluten-related disorders

Publications (1)

Publication Number Publication Date
IN2014DN10798A true IN2014DN10798A (en) 2015-09-04

Family

ID=49769279

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10798DEN2014 IN2014DN10798A (en) 2012-06-18 2013-06-18

Country Status (16)

Country Link
US (1) US10245300B2 (en)
EP (3) EP2861242B1 (en)
CN (1) CN104661671B (en)
AU (2) AU2013277316B2 (en)
BR (1) BR112014031666B1 (en)
CA (1) CA2876963C (en)
DK (2) DK3351554T3 (en)
ES (2) ES2883552T3 (en)
IN (1) IN2014DN10798A (en)
MX (1) MX363899B (en)
NZ (1) NZ702936A (en)
PL (2) PL2861242T3 (en)
PT (2) PT3351554T (en)
RU (1) RU2654705C2 (en)
TR (1) TR201814973T4 (en)
WO (1) WO2013192163A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171851A (en) 2011-06-20 2019-11-04 Heinz Co Brands H J Llc Probiotic compositions and methods
PL2994150T3 (en) 2013-05-10 2019-09-30 H.J. Heinz Company Brands Llc Probiotics and methods of use
AU2018207946A1 (en) * 2017-01-12 2019-07-25 Probi Ab Probiotic compositions and uses thereof
CN108567800A (en) * 2017-03-07 2018-09-25 景岳生物科技股份有限公司 use of lactobacillus paracasei strain GMN L-653 for the preparation of a composition for combating bone loss
KR102244007B1 (en) * 2019-02-14 2021-04-23 주식회사 메디뉴트롤 A composition for preventing, improving or treating gliadin-induced inflammatory bowel disease of the comprising lactobacillus paracasei glu70 having gluten degradation activity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1003929A (en) 1911-04-04 1911-09-19 Jacob T Lutz Trace-carrier.
EP0130228A1 (en) 1983-07-01 1985-01-09 Microlife Technics, Inc. Fermentation method using a selected lactobacillus
RU2134583C1 (en) 1996-02-29 1999-08-20 Санкт-Петербургская государственная педиатрическая медицинская академия Method of sanitation of women with massive microbe dissemination of breast milk
AU3173497A (en) 1996-06-21 1998-01-14 Quest International B.V. Fermentation of fruit products
SE510813C2 (en) 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bacterial strain of the species Lactobacillus Paracasei subsp. paracasei, its composition for use in food, and product containing the strain
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
FI110668B (en) 2000-06-20 2003-03-14 Aboatech Ab Oy Use of probiotics for primary prevention of atopic diseases
SE0003100D0 (en) 2000-09-01 2000-09-01 Probi Ab New strains
KR100419132B1 (en) 2000-12-29 2004-02-18 조성근 Lactobacillus paracasei subsp. paracasei CSK 01
US7303871B2 (en) 2002-02-14 2007-12-04 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
ES2311729T5 (en) 2002-06-28 2013-02-14 Biosearch S.A. Probiotic strains, a procedure for their selection, their compositions and their use
US7955834B2 (en) 2004-06-03 2011-06-07 Biogaia Ab Method for improved breast milk feeding to reduce the risk of allergy
WO2007066773A1 (en) 2005-12-08 2007-06-14 Kirin Holdings Kabushiki Kaisha Isohumulone compound clathrate and composition containing the same
US20110165127A1 (en) 2006-06-09 2011-07-07 Fabiola Masri Dairy-derived probiotic compositions and uses thereof
WO2008003782A1 (en) 2006-07-07 2008-01-10 Alpro Nv Method for preparing a dairy analogue
CN101451158A (en) 2007-12-04 2009-06-10 黑龙江大学 Separation and purification method of antibiotic peptides produced by Lactobacillus paracasei
EP2110027A1 (en) 2008-04-01 2009-10-21 Nestec S.A. Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation
BRPI0912106A2 (en) 2008-05-27 2015-10-13 Nestec Sa probiotics to improve intestinal microbiota
EP2138187A1 (en) 2008-06-24 2009-12-30 Nestec S.A. Probiotics, secretory IgA and infection
US20100196341A1 (en) 2009-02-05 2010-08-05 Syngen Biotech Co., Ltd. Novel Lactobacillus paracasei subsp. paracasei SG96, a Bacteriostatic Composition Containing the same and Use Thereof
EP2308498A1 (en) 2009-09-30 2011-04-13 Nestec S.A. Administration of Bifidobacterium breve during infancy to prevent inflammation later in life
US20130121976A1 (en) 2010-03-12 2013-05-16 Agusti Montserrat Carreras Lactic Acid Bacteria for Coeliac Disease
CN102021127B (en) 2010-07-28 2012-05-30 江南大学 Lactobacillus paracasei and application thereof
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
EP2449890A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Powdered cereal compositions comprising non-replicating probiotic microorganisms
EP2455094A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
EP2510932A1 (en) 2011-04-15 2012-10-17 Nestec S.A. Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny
MY171851A (en) 2011-06-20 2019-11-04 Heinz Co Brands H J Llc Probiotic compositions and methods
EP2761691A4 (en) 2011-09-28 2015-04-22 Phillips 66 Co Composite solid oxide fuel cell electrolyte
PL2994150T3 (en) 2013-05-10 2019-09-30 H.J. Heinz Company Brands Llc Probiotics and methods of use

Also Published As

Publication number Publication date
CN104661671B (en) 2020-10-23
AU2013277316A1 (en) 2015-01-22
PL2861242T3 (en) 2019-04-30
CA2876963C (en) 2021-07-06
EP3351554A1 (en) 2018-07-25
AU2018203543A1 (en) 2018-06-07
PT3351554T (en) 2021-08-06
CA2876963A1 (en) 2013-12-27
ES2691087T3 (en) 2018-11-23
DK2861242T3 (en) 2018-10-29
PT2861242T (en) 2018-11-07
RU2014150934A (en) 2016-08-10
MX2014015314A (en) 2015-10-29
PL3351554T3 (en) 2021-11-15
RU2654705C2 (en) 2018-05-22
US20150174199A1 (en) 2015-06-25
WO2013192163A1 (en) 2013-12-27
US10245300B2 (en) 2019-04-02
ES2883552T3 (en) 2021-12-09
EP2861242A4 (en) 2016-01-20
TR201814973T4 (en) 2018-11-21
EP2861242A1 (en) 2015-04-22
AU2018203543B2 (en) 2020-02-27
DK3351554T3 (en) 2021-08-30
MX363899B (en) 2019-04-05
AU2013277316B2 (en) 2018-03-01
NZ702936A (en) 2017-06-30
BR112014031666A2 (en) 2017-10-31
EP3901164A1 (en) 2021-10-27
EP3351554B1 (en) 2021-06-09
BR112014031666B1 (en) 2022-10-04
EP2861242B1 (en) 2018-08-08
CN104661671A (en) 2015-05-27

Similar Documents

Publication Publication Date Title
EA033689B9 (en) Inhibitors of kras g12c
MX2014003288A (en) Preparation and compositions of highly bioavailable zerovalent sulfur and uses thereof.
MX2020001212A (en) Anthracycline-based antibody drug conjugates having high in vivo tolerability.
IN2013CN01340A (en)
MX2013010343A (en) Compositions and methods for transplantation of colon microbiota.
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
MX2020012676A (en) Sustained-release dosage forms of ruxolitinib.
MX342675B (en) Stable formulations for parenteral injection of peptide drugs.
MX355036B (en) Synthetic nanocarrier combination vaccines.
IN2014DN10798A (en)
MX2014008706A (en) Tricyclic sulfonamide compounds and methods of making and using same.
TN2014000409A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
MX356671B (en) Methods of inhibition of protein fucosylation in vivo using fucose analogs.
WO2013022991A3 (en) Methods and compositions relating to p62 for the treatment and prophylaxis of cancer
MX348708B (en) Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate.
MX2015000338A (en) Novel strain of lactobacillus crispatus.
MX2015007584A (en) Triheptanoin for the treatment of glucose transporter 1 deficiency.
IN2015MN00027A (en)
MX2013005351A (en) Modified immune-modulating particles.
BR112013008749A2 (en) cyclosporine analogs
EP3528820C0 (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
EA201591758A8 (en) Sub-ADAMTS13 INTRODUCTION
MX2015005732A (en) Tricyclic compounds and methods of making and using same.
IN2014DN06738A (en)
MX356317B (en) Treatment of symptoms associated with female gastroparesis.